Novel small molecule that inhibits PAI-1 in development to slow vascular aging

3' education - Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Douglas E. Vaughan, MD - Northwestern University of Michigan, Chicago, IL, USA

An investigational inhibitor of plasminogen activator inhibitor type 1 (PAI-1) prevented arteriosclerosis in mice and prolonged life in mice with a rapid aging phenotype. As elevated PAI-1 may play a role in intravascular thrombosis, and since it is a marker of cellular senescence, the inhibitor is being developed to treat or slow down vascular aging. Phase 2 studies are being planned after phase I studies showed no sign of apparent toxicity.

Educational information

Vascular Biology Working Group Meeting at ACC 2016, Chicago, IL, USA

Disclosures

Douglas E. Vaughan, MD - Chair of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.